Re-engineering HA as a strategy to develop universal influenza vaccines
|
|
- Oscar Williamson
- 5 years ago
- Views:
Transcription
1 WHO Integrated Meeting on Development & Clinical Trials of Influenza Vaccines Re-engineering HA as a strategy to develop universal influenza vaccines Harry Kleanthous, Ph.D. Discovery Research January 24 th
2 Topics Background Target Product Profile Universal strategies Mapping the HA universe Consensus-based clustering (CBC s) SMARt 1 1
3 Background Universal influenza vaccine approaches have paradigm-shifting potential Goal is replacement of the seasonal vaccines Recent developments in the field offering protection against disease Promising targets Disruptive (change the influenza vaccination business model) By contrast, the clinical benefit of the majority of universal vaccine candidates in development (>40 candidates) limited to disease modulation Adjunct positioning M2e development efforts halted expensive and incremental benefit Approaches to universal flu vaccination have re-focused to sub-type universality Project established focusing on universal vaccine candidates offering protection against influenza disease 1 2
4 Background Re-engineered HA Conserved HA-stem sequences Conserved epitopes M1 M2e NP Strategy: Universal vaccines based on novel antigen constructs. Opportunity: A universal vaccine that protects against disease represents a significant opportunity to alter the current influenza vaccine landscape. 1 3
5 Universal Influenza vaccine targeting both A (H1 and H3) and B strains: Top-line TPP Composition Indications Target Popln. Target Markets Dosage & Administration Safety & Interactions Other Considerations Coverage of virus subtypes contained in regular QIV vaccines, One or more antigens may be required per virus subtype Assumption is that an adjuvant will be required Non-inferiority to standard-of-care flu vaccine at time of launch (replace seasonal vaccine) Standard-of-care at launch in the elderly segment is expected to be defined by improved flu vaccines (e.g. HDIM), possibly necessitating modifications e.g. adjuvant Protection against infection by a broad range of influenza virus subtypes and strains All age groups as for regular influenza vaccine Global vaccine IM (ID) administration Two or more initial doses, followed by repeat vaccination at intervals of several years Systemic and local reaction profiles comparable to marketed adjuvanted seasonal vaccines No clinically significant interference on co-administration with routine vaccinations A (pre-)pandemic indication will also be targeted as a second step Production should be high-yielding, readily-scalable using recombinant technologies permitting rapid and cost-effective production ( state-of-the-art manufacturing systems) The TPP fulfils a True Universal vaccine, covering all virus types ( optimal TPP ), and a Subtype Universal covering circulating virus types (i.e. H1, H3 and two B lineages; base case ) 1 4
6 Universal Influenza strategies Antigen Re-engineered & immune-refocused HA Sequence diversity Validation of designs Expression, folding & assessing breadth Alternate antigens (tetrameric NA) Adjuvants & delivery Breadth, magnitude and durability Route Antigen presentation (VLP, INV) Immunogenicity / Efficacy Role of pre-existing immunity Transmission Clinical Research 1 5
7 Strategy: HA as a Principal Component Generating novel, re-engineered antigens that induce a neutralizing antibody response against a broad-range of viruses (H1 POC) ANTIGENS Modified Full-Length HA (Re-engineered heads) HA-stem Headless-stem, chimeric HA, immune refocused HA NA tetramer (Univ. Ghent) DELIVERY SYSTEMS (Proprietary vectors) Split vaccine from Reverse Genetics Virus-Like Particles (VLPs) Vaccine with improved breadth of neutralization (POC) PROPRIETARY ADJUVANT 1 6
8 Scope of the problem: Breadth of Sequence Space for H1N1 0.1 H5N1: 263 unique sequences Overall Sequence Variation H5N1 H1N1 Pandemic current: 1956 unique sequences H1N1 % Sequence Identity : 1032 unique sequences 1 7
9 Universe of H1N1 Hemagglutinin Sequences H1 Strains to assess breadth (PRNT) A/Puerto Rico/8/ A/Fort Monmouth/1/1947 A/New Jersey 6 A/Brazil/11/ A/California/07/ A/Brisbane/59/2007 A/Solomon Islands/3/2006 A/Texas/36/1991 A/NewCaledonia/20/1999 PRNT assays established for each cluster 1 8
10 Strategy 1: Cluster-Based Consensus (CBC) Identification of most common amino acids at each position within and between H1N1 clusters followed by structure-guided optimization Cluster-based Consensus (CBC) Tier 1 Tier 2 Tier * * * * 1 * Denotes where cluster consensus matches circulating virus sequence 1 9
11 CBC designs recognized by neutralizing mab s (analogs) Re-engineered HA sequence retains proper folding of head and stem, as shown by binding of neutralizing mabs (FACS) (and sialic acid on RBCs) 2,000 1,500 1, ,000 C Ca09 NC99 PR8/34 HAco1M HAco2M HAco3M HAco4M HAco5M HAco6M HAco7M HAco8M HAcb12M HAcb345M HAcb67M 8_01 8_02 8_03 8_04 8_05 MFI 2,000 1,000 Ca09 NC99 0 3,000 CH65 PR8/34 HAco1M HAco2M HAco3M HAco4M HAco5M HAco6M HAco7M HAco8M HAcb12M HAcb345M HAcb67M 8_01 8_02 8_03 8_04 MFI 2,000 1,000 Ca09 NC99 0 4,000 5J8 PR8/34 HAco1M HAco2M HAco3M HAco4M HAco5M HAco6M HAco7M HAco8M HAcb12M HAcb345M HAcb67M 8_05 8_01 8_02 8_03 8_04 MFI 3,000 2,000 1,000 0 Okuno et al K8 Ca09 NC99 PR8/34 HAco1M HAco2M HAco3M HAco4M HAco5M HAco6M HAco7M HAco8M HAcb12M HAcb345M HAcb67M 8_05 8_01 8_02 8_03 8_04 8_05 MFI HEAD (EXPRESSION CORRECTED) STEM Whittle et al Krause et al Krause et al WT CBC Tier 1 CBC Tier 2 CBC Tier 3 Epitope shared with neutralized strains
12 Viable Influenza viruses rescued containing Consensus (CBC) HA s PR8 Backbone HA PB1 PB2 PA NP Consensus/ SMARt HA + PB1 PB2 PA NP NS M NA Rescued virus with Consensus HA HA titer Plaque Assay Rescued viruses Tier 1 Cluster 4 Tier 1 Cluster 5 Tier 2 Cluster :1000 1:1000 1:1000 >1x10^6 4.7x10^5 6.6x10^5 1 11
13 Breadth of neutralization (PRNT) induced by Tier1 (cluster 4) virus similar to NC 10 5 Tier viruses immunization (IN; 2x) day 35 HAco4M tier 1 New Caledonia WT Placebo 50% PRNT above placebo titer Cut 10 Off NS ** Heat map of sequence differences at key epitopes/antigenic regions % difference cluster California New Jersey Puerto Rico Texas New Caledonia 4 3 Brisbane Solomon Islands influenza strains ** P<0.01 Tukey-Kramer HSD test NC1999 reference seq. 1 12
14 Breadth of neutralization induced by Tier2 (clusters 345) virus similar to NC 50% PRNT above placebo titer cluster Cut Off Tier viruses immunization (IN; 2xl day 35) California New Jersey Puerto Rico 4 Texas ** New Caledonia 3 Brisbane *** Solomon Islands HAcb345M tier 2 Texas WT New Caledonia WT Brisbane WT Solomon Islands WT Placebo Heat map of sequence differences at key epitopes/antigenic regions % difference *** P<0.001 Tukey-Kramer HSD test influenza strains NC1999 reference seq. 1 13
15 HAI confirms limited breadth of initial prototypes Live WT virus (IN) versus live CBC Tier viruses (IN) day 35 (2x) HAI titer Cut off 10 1 anti-california (pools) anti-new Jersey (pools) anti-pr (pools) anti-texas (pools) anti-newcaledonia (pools) anti-brisbane (pools) anti-s o lo m o n Island (pools) 10 0 Placebo PBS Texas Texas New Cal New Caledonia Brisbane Brisbane Solomon Isl Solomon Isl Tier1co4M HAco4M Tier1co5M HAco5M HAcb345M Tier2cb345 Live virus (IN; 1 x10^5pfu) CBC Tier virus 14
16 Strategy 2: Structural Mapping of Antigenic Repertoires Expression and folding screen with mabs have yielded multiple SMARt candidates SMARt DESIGN Broadly neutralizing anti-stem & anti-head mabs demonstrate surface localization and folding Neutralizing Epitope #1 Influenza strain 1 Neutralizing Epitope #3 Influenza strain 3 VLPs prepared of SMARt HA candidates and assessing breadth of neutralizing antibody response with and without adjuvant Neutralizing Epitope #2 Influenza strain 2 Single HA molecule containing repertoires of neutralizing epitopes. Epitopes computationally assembled from diverse strains and carefully selected to collectively elicit broadly neutralizing antibodies Neutralizing Epitope #4 Influenza strain
17 Mosaic SMARt designs: Differences to NC99 template sequence CH65 HC45 FI6 SMARt_NC_CH2a SMARt_NC_CO1a SMARt_NC_DO1a SMARt_NC_RA3a (maximal strain coverage) (consensus epitope patterns) (dominant epitope patterns) (random combination of epitope patterns) Surface representation of trimeric HA with monomers colored blue green and gray. Amino acid differences between the designed molecule and the New Caledonia reference are highlighted in red. Fab fragments are docked onto the locations of three known neutralizing epitopes on the surface of HA: CH65, HC45 and FI6 1 16
18 SMARt designs appear well-folded and are functional Modification of HA sequence by SMARt method still retains proper folding of head and stem, as shown by binding of neutralizing mabs (FACS) 2,500 2,000 1,500 1,000 HEAD (EXPRESSION CORRECTED) STEM C179 Ca09 NC99 PR8/34 SMARtCH2a SMARtCH3a SMARtCO1a SMARtDO1a SMARtDO2a SMARtRA3a MFI 2,500 2,000 1,500 1, CH65 Ca09 NC99 PR8/34 SMARtCH2a SMARtCH3a SMARtCO1a SMARtDO1a SMARtDO2a SMARtRA3a MFI 2,500 2,000 1,500 1, J8 Ca09 NC99 PR8/34 SMARtCH2a SMARtCH3a SMARtCO1a SMARtDO1a SMARtDO2a SMARtRA3a MFI 3,500 3,000 2,500 2,000 1,500 1, K8 Ca09 NC99 PR8/34 SMARtCH2a SMARtCH3a SMARtCO1a SMARtDO1a SMARtDO2a SMARtRA3a MFI NC1999 reference seq. WT SMARt (NC99 backbone) Epitope shared with neutralized strains 1 17
19 SMARt HA proteins bind sialic acid on RBCs Immunogenicity and breadth of neutralization studies on-going 0 Mock A/New Caledonia A/California/07/2009 SMARtCH2a SMARtCH3a SMARtCO1a SMARtDO1a SMARtDO2a SMARtRA3a Assay performed using Guinea Pig RBCs NC SMARt Calif % RBC Binding Compared to New Caledonia 1 18
20 Conclusions Implemented strategy to evaluate re-engineered HA for increased breadth Mapped the evolution of influenza viruses Established bioinformatics approach to screen novel HA candidates Generated full-length consensus and mosaic HA that are properly folded & functionally active Viable viruses rescued with CBC HA s validates modeling approach Initial CBC designs (closely grouped clusters) did not increase breadth over wild type but approaches looking to increase breadth across multiple clusters appear promising (SMARt) NC99 is a broadly protective virus Test novel SMARt and Tier 3 CBC s in-vivo (+/- adjuvant) 1 19
21 Acknowledgements Bioinformatics: Tod Strugnell, Eliud Oloo, Ray Oomen Bacteriology: Tim Alefantis (PL), Guadalupe Cortes-Garcia, Qing-Sheng Gao Protein Chem: Fuqin Ma, Sophia Mundle, Jit Ray, Svetlana Stegalkina, Jix Zhang Steve Anderson Viral Immunology: Josh Dinapoli, Xiaochu Duan, Tim Farrell, Svetlana Pougatcheva, Darren Smith, Irina Ustyugova, Claire Ventura, Thorsten Vogel Animal Center: Johan Guerrero, Michael Howard, Lori Jasinski Management: Mark Parrington, Jeff Almond 1 20
Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationNature Immunology: doi: /ni Supplementary Figure 1. Infection strategy.
Supplementary Figure 1 Infection strategy. To test the antibody responses against influenza viruses, animals were sequentially infected with two divergent strains of the same subtype. For H1N1 infections,
More information24 26 January 2013, Hong Kong SAR, CHINA. TITLE from VIEW and SLIDE MASTER February 27, 2013
The first WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses 24 26 January 2013, Hong Kong SAR, CHINA 1 TITLE
More informationPATH Influenza Vaccine Projects
PATH Influenza Vaccine Projects Overview John W. Boslego, MD John Boslego Director, Vaccine Development Global Program March 25 th, 2014 Influenza Vaccine Project (IVP) at PATH IVP Goal: Advance the development
More informationBroadly protective influenza vaccines for pandemic preparedness. Suresh Mittal Department of Comparative Pathobiology Purdue University
Broadly protective influenza vaccines for pandemic preparedness Suresh Mittal Department of Comparative Pathobiology Purdue University Influenza A Virus Orthomyxovirus Consist of s/s (-) sense RNA 8 segments
More informationHemagglutinin-stalk specific antibodies: How to induce them and how to measure them
Immunodominant head domain Stalk domain Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them Florian Krammer Icahn School of Medicine at Mount Sinai May 5 th 2014 2 nd WHO
More informationUniversal Influenza Vaccine Development
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Universal Influenza Vaccine Development 2016 Global Vaccine and Immunization
More informationMedicago: transforming the approach to vaccines and protein-based therapeutics. Bruce D. Clark PhD President & CEO September 27, 2017
Medicago: transforming the approach to vaccines and protein-based therapeutics Bruce D. Clark PhD President & CEO September 27, 2017 Medicago Overview Focus Manufacturing technology Vaccine technology
More informationTOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/35908 holds various files of this Leiden University dissertation Author: Soema, Peter Title: Formulation of influenza T cell peptides : in search of a universal
More information7/14/2014 VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD)
7/14/214 VACCINATION & ENHANCED DISEASE VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD) HANA GOLDING & SURENDER KHURANA DIVISION OF VIRAL
More informationAn Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes. Nick Poulton June September 2012
An Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes Nick Poulton June 2012- September 2012 Epidemiology of Influenza Infection Causes between 250,000
More informationRecombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses Weimin Liu University of Alabama at Birmingham Introduction and Rationale Virus-like particles (VLPs)
More informationThe Influenza A (H1N1
The Influenza A (H1N1 Human Swine) Pandemic North America (A/Mexico/ /2009 [H1N1]), Influenza A virus, April 2009: - H1N1 & H3N2 viruses are endemic among pig populations in many countries - Reassortment
More informationBARDA INFLUENZA PROGRAM OVERVIEW
BARDA INFLUENZA PROGRAM OVERVIEW Drs. Armen Donabedian and Michael Wathen Vaccines and Therapeutics Resilient People. Healthy Communities. A Nation Prepared. 0 BARDA Overview 1 Perpetual challenge of responding
More informationPatterns of hemagglutinin evolution and the epidemiology of influenza
2 8 US Annual Mortality Rate All causes Infectious Disease Patterns of hemagglutinin evolution and the epidemiology of influenza DIMACS Working Group on Genetics and Evolution of Pathogens, 25 Nov 3 Deaths
More informationSynthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)
Synthetic Genomics and Its Application to Viral Infectious Diseases Timothy Stockwell (JCVI) David Wentworth (JCVI) Outline Using informatics to predict drift (strain selection) Synthetic Genomics: Preparedness
More informationDevelopment of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine
Development of safe and immunogenic reassortant viruses with 5:3 genotype for live attenuated influenza vaccine Irina Isakova-Sivak, PhD Institute of Experimental Medicine, Saint Petersburg, Russia The
More informationCristina Cassetti, Ph.D.
NIAID Extramural Research Update: Recombinant Influenza Viruses and Biosafety Cristina Cassetti, Ph.D. Influenza Program Officer Division of Microbiology and Infectious Diseases NIAID Influenza virus DMID
More informationProduct Development for Public Health & Emerging Infections
Product Development for Public Health & Emerging Infections Michael G Kurilla, MD-PhD Director, Office of BioDefense Research Affairs Division of Microbiology & Infectious Diseases Associate Director,
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationTransforming The Approach to Vaccines and Protein- Based Therapeutics. Alain Doucet, Ph.D. Manager, Process Development, Medicago
Transforming The Approach to Vaccines and Protein- Based Therapeutics Alain Doucet, Ph.D. Manager, Process Development, Medicago 2018-08-15 1 Medicago Overview 2 Novel Technologies 3 Robust Pipeline 2
More informationTechnology Overview. Summary
Live Attenuated Influenza Vaccines with Altered NS1 Technology Overview Summary Transformative Technology: Live attenuated influenza vaccines (LAIVs) with precise, genetically stable truncations of the
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationRegulatory requirements for universal flu vaccines Perspective from the EU regulators
Regulatory requirements for universal flu vaccines Perspective from the EU regulators EDUFLUVAC workshop 12-14 June Marco Cavaleri Head of Anti-infectives and Vaccines Scientific & Regulatory Management
More informationFlu, Avian Flu and emerging aspects (H1N1 resistance)
EU-CIS Seminar New trends in Infectious Diseases 26 28 November 2008 / Lyon, France Flu, Avian Flu and emerging aspects (H1N1 resistance) Pr. Florence MORFIN FRE 3011 Université Lyon 1 - CNRS Laboratory
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationModeling the Antigenic Evolution of Influenza Viruses from Sequences
Modeling the Antigenic Evolution of Influenza Viruses from Sequences Taijiao Jiang Center of Systems Medicine, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine October 8-10, 2015.
More informationWhat are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific
14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on
More informationUpdate on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
More informationNovel Flu Vaccines Lots of choices
Novel Flu Vaccines Lots of choices Universal M2 ectodomain (A types, only) Universal HA cleavage site (A and B types) HA made by rdna methods (not eggs or mammalian cells) Vectored delivery of HA genes
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationUniversity of Groningen
University of Groningen Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization Brandenburg, Boerries; Koudstaal, Wouter; Goudsmit, Jaap; Klaren, Vincent; Tang, Chan; Bujny, Miriam V.; Korse,
More informationINFLUENZA EVOLUTION: Challenges for diagnosis
INFLUENZA EVOLUTION: Challenges for diagnosis Jairo A. Méndez-Rico Influenza Team PAHO/WHO, Washington, DC Overview Every year, influenza infects up to one in five people around the world, and causes up
More informationDevelopment of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine
Development of Recombinant MERS-CoV Spike (S) Nanoparticle Vaccine Russell P. Wilson Senior Vice President, Business Development Vaccine World MENA & CIS 2014 Istanbul, Turkey November 19, 2014 1 www.novavax.com
More informationE.J. Remarque & G. Koopman. Confiden'al 2
EDUcate influenza VACcine A Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure Confiden'al
More informationSummary of Current Respiratory Season and Genetic Analysis of Influenza Virus Circulating in Alberta
Laboratory Bulletin Date: February 28, 2013 To: From: Re: Alberta Health, Alberta MicroNet, Communicable Disease Nurses, Infectious Diseases Physicians, Infection Prevention and Control, Medical Officers
More informationAn Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)
An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines
More informationH3N2 Mismatch of Northern Hemisphere Influenza Vaccines and Head-to- head Comparison between Human and Ferret Antisera derived Antigenic Maps
1 2 H3N2 Mismatch of 2014 15 Northern Hemisphere Influenza Vaccines and Head-to- head Comparison between Human and Ferret Antisera derived Antigenic Maps 3 4 5 6 7 Hang Xie 1*, Xiu-Feng Wan 2*, Zhiping
More informationInfluenza surveillance and pandemic preparedness - a global challenge Anne Kelso
Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza Melbourne, Australia Three global health challenges 243
More informationNew Technology in Vaccine Engineering
Viruses in May Katoomba, August, 2012 New Technology in Vaccine Engineering Anton Middelberg Australian Institute for Bioengineering and Nanotechnology The University of Queensland, Australia Introduction
More information100 years of Influenza Pandemic and the prospects for new influenza vaccines
100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London
More informationLecture 19 Evolution and human health
Lecture 19 Evolution and human health The evolution of flu viruses The evolution of flu viruses Google Flu Trends data US data Check out: http://www.google.org/flutrends/ The evolution of flu viruses the
More informationIdentification of Mutation(s) in. Associated with Neutralization Resistance. Miah Blomquist
Identification of Mutation(s) in the HIV 1 gp41 Subunit Associated with Neutralization Resistance Miah Blomquist What is HIV 1? HIV-1 is an epidemic that affects over 34 million people worldwide. HIV-1
More informationPredicting the future
Swine influenza A viruses: a more global picture Predicting the future Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Centre for for Pathogen Evolution and WHO Collaborating
More informationREPORT DOCUMENTATION PAGE
REPORT DOCUMENTATION PAGE Form Approved OMB NO. 0704-0188 The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions,
More informationAcute respiratory illness This is a disease that typically affects the airways in the nose and throat (the upper respiratory tract).
Influenza glossary Adapted from the Centers for Disease Control and Prevention, US https://www.cdc.gov/flu/glossary/index.htm and the World Health Organization http://www.wpro.who.int/emerging_diseases/glossary_rev_sept28.pdf?ua=1
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationIdentification of novel influenza A viruses in Australian swine
Identification of novel influenza A viruses in Australian swine OFFLU SIV Group Annual Meeting, Rome, 16-17 April 2013 Frank Wong 1, Ian Barr 2, David Smith 3, David Williams 1, Kelly Davies 1, Vicky Stevens
More informationImmunogenicity of Avian Influenza H7N9 Virus in Birds
Immunogenicity of Avian Influenza H7N9 Virus in Birds Identification of Viral Epitopes Recognized by the Immune System Following Vaccination and Challenge Darrell R. Kapczynski US DEPARTMENT OF AGRICULTURE,
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationCationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants
Cationic Liposome-DNA Complexes as Immunomodulators and Vaccine Adjuvants September 29, 28 Platform Technology Proprietary Cationic Lipid-DNA Complexes Cationic/Neutral Lipid + DNA = JVRS-1 JVRS-1 + Antigen
More informationWHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More informationVIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks
INFLUENZA VIROLOGY OF INFLUENZA Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks PATHOGENICITY High pathogenicity avian influenza (HPAI) Causes severe disease in poultry
More informationUniversity of Colorado Denver. Pandemic Preparedness and Response Plan. April 30, 2009
University of Colorado Denver Pandemic Preparedness and Response Plan April 30, 2009 UCD Pandemic Preparedness and Response Plan Executive Summary The World Health Organization (WHO) and the Centers for
More informationThe "Flu" a case of low fever and sniffles that keeps you home in bed for a day a gastrointestinal upset ("stomach flu")
The "Flu" Influenza is a viral infection of the lungs characterized by fever, cough, and severe muscle aches. In the elderly and infirm, it is a major cause of disability and death (often as a result of
More informationSupplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationBRIEF REPORT. The degree of immunity to pandemic influenza A(H1N1) 2009 (hereafter pandemic H1N1) in humans positively correlates
BRIEF REPORT Inactivated Seasonal Influenza Vaccines Increase Serum Antibodies to the Neuraminidase of Pandemic Influenza A(H1N1) 2009 Virus in an Age-Dependent Manner Glendie Marcelin, 1 Hilliary M. Bland,
More informationCombinatorial Vaccines for AIDS and other Infectious Diseases
Dale and Betty Bumpers Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services Combinatorial Vaccines for AIDS
More informationph1n1 H3N2: A Novel Influenza Virus Reassortment
ph1n1 H3N2: A Novel Influenza Virus Reassortment Jonathan Gubbay Medical Microbiologist Public Health Laboratory Public Health Ontario June 16, 2011 ph1n1 H3N2 Reassortment: Talk Overview Explain strain
More informationAvian influenza and pandemic threats
Avian influenza and pandemic threats Philippe BUCHY MD, PhD Head of Virology Unit Director NIC Cambodia Vaccinology 2013 Bangkok, 11-13 November 2013 Influenza viruses Influenza viruses (Orthomyxoviridae)
More informationC E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock
C E E Z A D Center of Excellence for Emerging and Zoonotic Animal Diseases A Department of Homeland Security Center of Excellence Rational Development of Influenza Vaccines: NDV-based influenza vaccines
More informationInfluenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
More informationHigh frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland
Research articles High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland N Ikonen (niina.ikonen@thl.fi) 1, M Strengell 1, L Kinnunen 2, P
More informationThe Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines
The Expanding Rotavirus Vaccine Landscape: Lessons learned from Influenza Vaccines Kathleen Neuzil, MD, MPH Director, Center for Vaccine Development University of Maryland School of Medicine September
More informationFluSure XP TM Update with Regards to 2009 H1N1 Swine Influenza Virus
FluSure XP TM Update with Regards to 2009 H1N1 Swine Influenza Virus Although the 2009 H1N1 swine influenza virus has not been identified in US swine herds, it should be noted that swine influenza vaccines,
More informationCenters for Disease Control and Prevention U.S. INFLUENZA SEASON SUMMARY*
1 of 8 11/8/2012 1:36 PM Centers for Disease Control and Prevention 2005-06 U.S. INFLUENZA SEASON SUMMARY* NOTE: This document is provided for historical purposes only and may not reflect the most accurate
More informationGSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationHighly efficacious influenza vaccination using αgal carbohydrate modification
Highly efficacious influenza vaccination using αgal carbohydrate modification Brian K. Martin, Ph.D. Director, Infectious Disease Division BioProtection ystems A wholly-owned subsidiary of NewLink Genetics
More informationForward Looking Statements
Antiviral Therapies Forward Looking Statements This presentation contains forward-looking statements, including the timing of our drug development programs. Risks include delays in manufacturing created
More informationProspect of Universal Influenza Vaccine Designed by Broadly Neutralizing Monoclonal Antibodies (1) Yoshinobu Okuno
Vaccine World East Asia 2015 Seoul, January 26, 2015 Prospect of Universal Influenza Vaccine Designed by Broadly Neutralizing Monoclonal Antibodies (1) Yoshinobu Okuno The Research Foundation for Microbial
More informationPreferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after H7N9 immunization in humans
INFECTIOUS DISEASE Preferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after immunization in humans Sarah F. Andrews, 1 * M. Gordon Joyce, 1 Michael J. Chambers,
More informationNoroviruses. Duncan Steele Bill & Melinda Gates Foundation. Acknowledgements: Ben Lopman and Umesh Parashar, CDC Megan Carey and Julia Bosch, BMGF
Noroviruses Duncan Steele Bill & Melinda Gates Foundation Acknowledgements: Ben Lopman and Umesh Parashar, CDC Megan Carey and Julia Bosch, BMGF 1 Global norovirus burden Globally, norovirus is associated
More informationBoosts Following Priming with gp120 DNA
Neutralizing Antibody Responses Induced with V3-scaffold Protein Boosts Following Priming with gp120 DNA Susan Zolla-Pazner NYU School of Medicine Problems with Whole Env Immunogens Poor induction of Abs
More informationCorrelates of Protection for Flu vaccines and Assays Overview. by Simona Piccirella, PhD Chief Executive Officer
Correlates of Protection for Flu vaccines and Assays Overview by Simona Piccirella, PhD Chief Executive Officer Company Overview: VisMederi is an Italian private small enterprise established in 2009 and
More informationEmerging infectious threats in Indigenous populations
Emerging infectious threats in Indigenous populations Dr Jane Davies NHMRC Senior Research Fellow Menzies School of Health Research Infectious Diseases Physician Royal Darwin Hospital Facts & figures Why
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBjoern Peters La Jolla Institute for Allergy and Immunology Buenos Aires, Oct 31, 2012
www.iedb.org Bjoern Peters bpeters@liai.org La Jolla Institute for Allergy and Immunology Buenos Aires, Oct 31, 2012 Overview 1. Introduction to the IEDB 2. Application: 2009 Swine-origin influenza virus
More informationAn epitope of limited variability as a novel influenza vaccine target
An epitope of limited variability as a novel influenza vaccine target Craig P Thompson 1,2*, José Lourenço 1, Adam A Walters 2, Uri Obolski 1, Matthew Edmans 1,2, Duncan S Palmer 1, Kreepa Kooblall 3,
More informationTalkin Flu Mid-America Immunization Coalition August 18, William Atkinson, MD, MPH Immunization Action Coalition
Talkin Flu Mid-America Immunization Coalition August 18, 2016 William Atkinson, MD, MPH Immunization Action Coalition Disclosures William Atkinson has worked as a consultant to Merck and as a speaker for
More informationDevelopment of a Recombinant Subunit Dengue Vaccine. Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller
Development of a Recombinant Subunit Dengue Vaccine Flavivirus Vaccination Fondation Mérieux December 8, 2010 Beth-Ann Coller Recombinant Subunit Dengue Vaccine Recombinant Envelope Protein Vaccine Hawaii
More informationVaccine. Design and Manufacturing. Liting Bi. https://en.wikipedia.org/wiki/vaccine
Vaccine Design and Manufacturing Liting Bi https://en.wikipedia.org/wiki/vaccine 1 Outline Vaccine Intro. 4 Vaccine Types 2 Manufacturing Methods 2 Tests & Applications Take-home messages 2 https://www.youtube.com/watch?v=t_me5ef0ne4
More informationLive Attenuated Influenza Vaccine. I. Background and Seasonal Vaccine
Live Attenuated Influenza Vaccine I. Background and Seasonal Vaccine Influenza infection stimulates multiple arms of the immune system Systemic antibody to HA and NA, and multiple internal proteins Mucosal
More informationPlant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing
Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures
More informationOrigins and evolutionary genomics of the novel avian-origin H7N9 influenza A virus in China: Early findings
Origins and evolutionary genomics of the novel 2013 avian-origin H7N9 influenza A virus in : Early findings Jiankui He*, Luwen Ning, Yin Tong Department of Biology, South University of Science and Technology
More informationTargeted disruption of influenza A virus hemagglutinin in genetically modified. mice reduces viral replication and improves disease outcome
Supplementary Information Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome Song Wang 1#, Chao Chen 1#, Zhou Yang
More informationChallenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats
Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats Susan Dana Jones, Ph.D. BioProcess Technology Consultants, Inc. BIO 2009 Process Zone Theater Atlanta, GE May 20, 2009
More informationNew prospects for vaccination: from polio to dengue and flu
New prospects for vaccination: from polio to dengue and flu From ancient Chinese variolation to Jenner and cowpox Paul Young Australian Infectious Diseases Research Centre School of Chemistry and Molecular
More informationInfluenza VE studies in Australia
Influenza VE studies in Australia Heath Kelly Head, Epidemiology Unit, Victorian Infectious Diseases Reference Laboratory Adjunct Professor, National Centre for Epidemiology and Population Health, Australian
More informationTITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?
TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important? AUTHORS: Joshua G. Petrie 1, Adam S. Lauring 2,3 AFFILIATIONS: 1 Department of Epidemiology, University of
More informationEMA guidelines on influenza vaccines
EMA guidelines on influenza vaccines High level hearing on the implementation of the Council Recommendation on seasonal influenza vaccination Presented by Manuela Mura on 30 April 2015 Scientific Officer
More information10/6/2014. INFLUENZA: Why Should We Take The Vaccine? OUTLINE INFLUNZA VIRUS INFLUENZA VIRUS INFLUENZA VIRUS
INFLUENZA: Why Should We Take The Vaccine? Baptist Hospital Baptist Children s Hospital Doctors Hospital J. Milton Gaviria, MD, FACP October 17, 2014 Homestead Hospital Mariners Hospital Baptist Cardiac
More information